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Abstract
Background:  The incidence of malignant pleural mesothelioma (MPM) is associated with
exposure to asbestos, and projections suggest that the yearly number of deaths in Western Europe
due to MPM will increase until 2020. Despite progress in chemo- and in multimodality therapy,
MPM remains a disease with a poor prognosis. Inducing apoptosis by tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or agonistic monoclonal antibodies which target TRAIL-receptor
1 (TRAIL-R1) or TRAIL-R2 has been thought to be a promising cancer therapy.
Results: We have compared the sensitivity of 13 MPM cell lines or primary cultures to TRAIL and
two fully human agonistic monoclonal antibodies directed to TRAIL-R1 (Mapatumumab) and
TRAIL-R2 (Lexatumumab) and examined sensitization of the MPM cell lines to cisplatin-induced by
the TRAIL-receptor antibodies. We found that sensitivity of MPM cells to TRAIL, Mapatumumab
and Lexatumumab varies largely and is independent of TRAIL-receptor expression. TRAIL-R2
contributes more than TRAIL-R1 to death-receptor mediated apoptosis in MPM cells that express
both receptors. The combination of cisplatin with Mapatumumab or Lexatumumab synergistically
inhibited the cell growth and enhanced apoptotic death. Furthermore, pre-treatment with cisplatin
followed by Mapatumumab or Lexatumumab resulted in significant higher cytotoxic effects as
compared to the reverse sequence. Combination-induced cell growth inhibition was significantly
abrogated by pre-treatment of the cells with the antioxidant N-acetylcysteine.
Conclusion:  Our results suggest that the sequential administration of cisplatin followed by
Mapatumumab or Lexatumumab deserves investigation in the treatment of patients with MPM.
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Background
Malignant pleural mesothelioma (MPM) is a generally
fatal thoracic neoplasia that arises from the pleural lining.
In the majority of the patients, a history of occupational
exposure to asbestos can be elicited [1]. Taking into
account a latency period of 20–50 years and a decline in
workplace exposure to asbestos in Europe since the 1970s,
it is estimated that the number of men dying from MPM
in Europe will double each year until a peak is reached in
about between 2015 and 2020 [2,3].
No chemotherapy regimen for mesothelioma has proven
curative, although several treatments are valuable for pal-
liation. The clinically best documented chemotherapy is a
combination of cisplatin with an antifolate. A large phase
III study comparing the combination of cisplatin and
pemetrexed with cisplatin alone demonstrated a superior
response, survival and a better quality of life for the com-
bination [4,5]. For earlier stages of disease, specialized
centers offer multimodality therapy with adjuvant or neo-
adjuvant chemotherapy, radical surgery with or without
radiotherapy [6]. However, despite such aggressive treat-
ment most patients have disease recurrence within 2
years. Therefore, new therapeutic options are needed for
more effective treatment of this malignancy. As demon-
strated by our in vitro investigations, the combination of
cisplatin-based chemotherapy with agonistic TRAIL recep-
tor antibodies might be a promising option.
Tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL) is a type II transmembrane protein belong-
ing to the TNF family of death ligands. Four TRAIL recep-
tors have been identified of which two, TRAIL-R1/DR4
and TRAIL-R2/DR5, are capable of transducing an apop-
totic signal whereas the other two receptors (TRAIL-R3/
DcR1, TRAIL-R4/DcR2) act as antagonists since they lack
death domains and thus cannot engage the apoptotic
machinery [7,8]. An additional receptor, osteoprotegrin,
has been identified but its activity is still matter of debate
because of its low affinity for TRAIL at 37°C [9]. TRAIL
can preferentially induce apoptosis in a variety of tumor
cell types, whereas normal cells do not appear to be sensi-
tive [10]. This property suggests TRAIL-R targeting is an
excellent strategy for selective cancer therapy and oncol-
ogy trials with TRAIL and TRAIL-R human agonistic anti-
bodies have been initiated [11,12].
Apoptosis-inducing mechanisms by human agonistic
TRAIL-R antibodies Mapatumumab and Lexatumumab
are thought to be similar to TRAIL-mediated apoptosis
[13]. TRAIL-induced cell death is triggered by the interac-
tion of the ligand with TRAIL-R1 or TRAIL-R2 to assemble
the death-inducing signaling complex. The latter forms
when death receptor ligation triggers association of the
intracellular adaptor, Fas-associated death domain
(FADD) with the cytoplasmic tail of the receptor. FADD
then recruits procaspase-8, which undergoes spontaneous
autoactivation. Activated caspase-8, in turn, cleaves and
activates the effector caspases-3, -6 and -7 which cleave
cellular substrates to execute cell death [7,8]. Recent data
suggest the existence of considerable cross-talk between
the extrinsic and intrinsic death signalling pathways. Cas-
pase-8, a key player of this communication platform, can
proteolytically activate the BH3 only family member Bid,
which induces Bax- and Bak-mediated release of cyto-
chrome c and Smac/DIABLO from mitochondria [14].
Resistance to TRAIL can occur by different mechanisms,
including lack of TRAIL apoptosis receptors, death recep-
tor mutations [15], and enhanced expression of TRAIL-
decoy receptors [16]. FLIP, which bears structural similar-
ity to caspase-8, but lacks caspase-8 activity, can inhibit
death receptor-mediated signalling by binding to FADD
[17]. Both forms of FLIP, the long form c-FLIPL and the
short form c-FLIPS can compete for apical caspase recruit-
ment to the DISC, whereas FLIPL can also inhibit the full
processing of caspase-8 [18].
MPM cells have been found by others to be resistant or to
have a low susceptibility to TRAIL-induced apoptosis, and
require either FLIPL siRNA, chemotherapeutic drugs, α-
tocopheryl succinate or cycloheximide to be combined
with TRAIL for apoptosis to occur [19-22]. However, these
studies were performed with a small number of estab-
lished human MPM cell lines only and it remains
unknown whether the majority of MPM cell lines and pri-
mary cultures are indeed resistant to TRAIL combined
with chemotherapy. In addition, no information exists on
the sensitivity of MPM cells to two fully human agonistic
monoclonal antibodies which target TRAIL-R1 (Mapatu-
mumab) and TRAIL-R2 (Lexatumumab) although they
have the advantage over TRAIL of a longer plasma half-life
and a higher specificity [23].
In the present study, we compared the sensitivity of 13
MPM cell lines or primary cultures to TRAIL and to two
fully human agonistic monoclonal antibodies which tar-
get TRAIL-R1 and TRAIL-R2, and examined the apoptosis
sensitization of the MPM cell lines with different sensitiv-
ity to Mapatumumab or Lexatumumab by the cytotoxic
drug cisplatin.
Results
Expression of TRAIL receptors in MPM cell lines or 
primary cultures
The expression of the four membrane-bound TRAIL-
receptors was analyzed in a large panel of commercially
available and well-established MPM cells lines obtained
from human biopsies or pleural effusions [24,25]. Flow
cytometry analyses performed on non-permeabilized cells
with monoclonal antibodies raised against the extracellu-Molecular Cancer 2007, 6:66 http://www.molecular-cancer.com/content/6/1/66
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lar domains of TRAIL-R1 and -R2, respectively, demon-
strated expression of both receptors at the cell surface of
MPM cells, with higher TRAIL-R2 than TRAIL-R1 expres-
sion in the majority of cells analysed (Table 1). In con-
trast, the two decoy receptors TRAIL-R3 and -R4 were
either not detected or expressed at the very low levels at
the cell surface of all cell lines (Table 1).
Activity of TRAIL in MPM cell lines or primary cultures
We have explored the biological effect of recombinant
human TRAIL on MPM cells. For this purpose, 13 MPM
cells lines were treated with 100 ng/ml His-TRAIL for 72
h, and cell viability was measured. Jurkat T cell leukemic
cells are sensitive to TRAIL-mediated cell killing [26] and
were used as a positive control. A significant inhibitory
effect of TRAIL could be observed in all 13 tested cell lines
(Figure 1). In detail, seven (MSTO-211H, SDM4, H28,
ZL55, ZL5, SPC111, H2452,) were sensitive (defined as
>60% cell death), two (SDM13, SDM6) were partially
resistant (defined as 20–60% cell death) and the remain-
ing four (H2052, SPC212, ZL34 and H226) were resistant
(defined as < 20% cell death) to TRAIL. These data dem-
onstrate that sensitivity of MPM cells to TRAIL is very het-
erogeneous. There was no correlation between the level of
TRAIL death receptor expression and sensitivity to TRAIL.
Activity of agonistic fully human anti-TRAIL death 
receptor monoclonal antibodies Mapatumumab and 
Lexatumumab in MPM cell lines or primary cultures
TRAIL-R1 and -R2 may be differentially involved in trans-
mitting apoptotic signals [10,27,28] and the relative con-
tribution of each death receptor to apoptosis induction in
MPM cells expressing both receptors is unknown. To
investigate the relative contribution of TRAIL-R1 and -R2
in apoptosis induction, MPM cell lines and primary cul-
tures were incubated with increasing concentrations of
specific human selective agonistic monoclonal antibodies
for 72 h. Six out of thirteen MPM cell lines were more sen-
sitive to Lexatumumab than to Mapatumumab (SDM13,
ZL34, SDM6, SDM4, H2452, ZL5) and only two out of
thirteen were more sensitive to Mapatumumab (MSTO-
211H, H28) (Figure 2 and Table 2). Two cell lines showed
similar sensitivity to Mapatumumab and Lexatumumab
(ZL55, SPC111) and almost complete resistance to both
antibodies (10 µg/ml) was detected in three cell lines
(H2052, SPC212, H226). As observed for TRAIL, no cor-
relation between the level of receptor expression (Table 1)
and the sensitivity to antibodies could be found.
Cisplatin sensitizes MPM cells to Mapatumumab- or 
Lexatumumab- mediated cytotoxicity
Several studies have shown that chemotherapeutic agents
and radiotherapy sensitize tumor cells to Mapatumumab
or Lexatumumab [29]. Therefore we tested how pre-treat-
ment with cisplatin affects the response to agonist-TRAIL
receptor antibodies in the MPM cell lines H226 and ZL55,
which are agonist-TRAIL receptor antibodies resistant and
sensitive, respectively. Incubation of H226 cell line with 2
µM cisplatin alone resulted in 29% cell death and addi-
tion of either Mapatumumab or Lexatumumab 24 h later
(both at 10 µg/ml) did not significantly increase dead cell
fraction (Fig. 3). However, a synergistic effect of cisplatin
and agonist TRAIL receptor antibodies was observed in
ZL55 cell line (Fig. 3).
Table 1: Evaluation of TRAIL receptors cell surface expression in MPM cell lines. Expression of TRAIL-R1, TRAIL-R2, TRAIL-R3 and 
TRAIL-R4 was evaluated by flow cytometry. The values represent the fluorescence intensity of the receptors normalized for the 
negative control. Data are expressed as mean ± s.d. from three independent experiments. *n.e.-not expressed
TRAIL-receptors
MPM cell lines TRAIL-R1 TRAIL-R2 TRAIL-R3 TRAIL-R4
TRAIL-resistant
H2052 14.0 ± 0.4 58.0 ± 3.1 2.6 ± 0.1 1.7 ± 0.4
SPC212 30.5 ± 0.2 64.0 ± 2.4 1.2 ± 0.1 4.2 ± 0.8
ZL34 10.9 ± 0.5 65.5 ± 4.2 1.5 ± 0.2 2.0 ± 0.5
H226 12.7 ± 0.8 66.6 ± 6.5 n.e* n.e
TRAIL-partially resistant
SDM6 15.8 ± 0.3 33.6 ± 3.2 1.3 ± 0.1 n.e
SDM13 10.3 ± 0.2 15.3 ± 0.4 1.2 ± 0.3 1.4 ± 0.2
TRAIL-sensitive
H2452 1.5 ± 0.1 34.0 ± 2.0 2.5 ± 0.2 1.7 ± 0.3
SCP111 33.0 ± 1.0 33.6 ± 1.5 2.1 ± 0.2 1.5 ± 0.2
ZL5 13.2 ± 0.2 55.7 ± 3.2 1.1 ± 0.1 1.3 ± 0.2
ZL55 32.8 ± 2.0 38.2 ± 3.5 n.e 1.2 ± 0.4
H28 26.4 ± 0.4 22.0 ± 0.8 1.3 ± 0.2 2.5 ± 0.5
SDM4 24.5 ± 0.3 58.0 ± 4.2 1.4 ± 0.2 1.5 ± 0.1
MSTO-211H 2.3 ± 0.1 60.4 ± 3.2 1.3 ± 0.3 1.3 ± 0.2Molecular Cancer 2007, 6:66 http://www.molecular-cancer.com/content/6/1/66
Page 4 of 13
(page number not for citation purposes)
To further characterize cisplatin-induced sensitization, we
compared the effects of concurrent treatment with cispla-
tin and agonist TRAIL receptor antibodies in the cell lines
ZL5 (sensitive only to Lexatumumab) and H28 (sensitive
to both Mapatumumab and Lexatumumab). The synergy
was evaluated in ZL5 cells exposed to single treatment or
combinations of 2.12 µM cisplatin (IC50) and/or 1.01 µg/
ml Lexatumumab (IC25) or fractions/multiples of those
concentrations at a constant ratio from 0.25- to 4-fold
(Fig. 4). Synergy was quantified by Combination Index
(CI) analysis and expressed as CI versus fraction affected.
By this method, CI<1 indicates synergy; CI = 1 indicates
an additive effect; and CI>1 indicates antagonism. 96%
confidence intervals are shown on CI plots. Low doses
(0.25 and 0.5 times cisplatin IC50) of combined treat-
ment with cisplatin and Lexatumumab resulted in
decreased cell growth of ZL5 cells compared to single
agent-treatments although no synergistic effect was detect-
able. Higher doses (1–4 times cisplatin IC50) of cisplatin
and Lexatumumab reduced cell growth synergistically
compared to either agent alone, with CI values lower than
0.6 (Fig. 4).
When the same strategy was applied to H28 cells, reduced
cell growth was observed after treatment with low doses
(0.25 times cisplatin IC50) of cisplatin in combination
with Mapatumumab or Lexatumumab compared to single
agent treatments but no synergism was detectable. How-
ever, higher doses (0.5–4 times cisplatin IC50) of cisplatin
in combination with Mapatumumab or Lexatumumab
synergistically inhibited cell growth, with CI values
decreasing from 0.9 to 04 and from 0.7 to 0.4 for cisplatin
in combination with Mapatumumab or Lexatumumab,
respectively (Fig. 4).
Taken together, these results indicate that both, cisplatin
pre- or concurrent treatment, are able to modulate the
response induced by anti-TRAIL receptor antibodies Map-
atumumab/Lexatumumab.
Post- but not pre-treatment with agonist TRAIL receptor 
antibodies enhances cisplatin cytotoxicity in MPM cells
We examined whether the synergistic interaction between
agonist TRAIL receptor antibodies and cisplatin changes
when both the sequence and the time interval between
the two treatments were varied in H28 cells. The cytotox-
icity was not significantly enhanced by pre-treating the
cells with either Mapatumumab or Lexatumumab, fol-
lowed by subsequent cisplatin treatment, even when the
time interval between the two treatments was increased
up to 24 h (Fig. 5). Interestingly, increasing the time
between cisplatin-treatment and subsequent treatment
with either Mapatumumab or Lexatumumab did gradu-
ally increase the cytotoxic effects of both combinations
over time in (Fig. 5).
Pre-treatment of H28 cells with cisplatin followed by
treatment with either Mapatumumab or Lexatumumab
resulted in 69% and 73% reduction in cell viability after
24 h for cisplatin with Mapatumumab or Lexatumumab,
respectively (Fig. 5).
Thus, our findings highlight the importance of sequential
administration of the drugs to increase the synergy.
Cisplatin facilitates TRAIL receptor antibodies-mediated 
apoptosis
Mapatumumab, Lexatumumab and cisplatin are able to
activate caspases [29-31]. To determine the molecular
mechanisms involved in cisplatin enhancement of apop-
tosis induced by antibodies, four MPM cell lines with dif-
ferent sensitivities to Mapatumumab and/or
Lexatumumab (H28, ZL5, ZL55 and H226, see Table 2)
were treated with Mapatumumab or Lexatumumab in the
presence or absence of cisplatin. Caspase 8, caspase 3
pathway and anti- or pro-apoptotic protein levels were
measured to investigate the induction of apoptosis (Fig.
6A and Fig. 6B). Mapatumumab treatment led to cleavage
of the TRAIL death effectors caspase 8 and Bid in H28 and
ZL55 as would be expected based on results obtained by
cytotoxicity assay. In ZL55 and to a lesser degree in H28
cells, Bid cleavage seems sufficient to trigger the intrinsic
apoptosis pathway since activation of caspase 3 and cleav-
age of its substrate ICAD were observed (Fig. 6A). On the
other hand, Lexatumumab, stimulated the TRAIL apop-
Activity of TRAIL in MPM cell lines or primary cultures Figure 1
Activity of TRAIL in MPM cell lines or primary cul-
tures. Jurkat T cell leukemic cells (black column), commer-
cially available and/or well-established MPM cell lines (grey 
columns) and primary MPM cultures (white columns) were 
incubated with 100 ng/ml His-TRAIL, and cell proliferation 
was determined by MTT assay 72 h thereafter. Absorbance 
values obtained with untreated cells maintained under identi-
cal conditions were taken as 100%. Data represent means of 
three independent experiments and bars indicate standard 
deviations. **, P < 0.01 and *, P < 0.05 compared to 
untreated cells.
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totic pathway as expected in ZL5 and ZL55 (Fig. 6B). Cis-
platin, which alone mainly increased BAX levels in all cell
lines, in combination with Mapatumumab seemed to
lower the threshold of extrinsic pathway stimulation since
increased cleavage of TRAIL effectors was observed. A sim-
ilar synergistic effect was observed by concurrent treat-
ment with cisplatin and Lexatumumab in ZL5, and ZL55
cells compared to Lexatumumab alone. Little cleavage of
TRAIL effectors was observed in the TRAIL resistant cell
line H226 (Fig. 6A and Fig. 6B).
The most prominent increase in the processing of intrinsic
pathway effectors caspase-3 and the caspase-3 targets
ICAD and Mcl-1 were found in all tested cells lines after
treatment with cisplatin in combination with either Map-
atumumab or Lexatumumab (Fig. 6A and Fig. 6B).
Two recent studies, including ours, demonstrated that cis-
platin-induced DNA damage up-regulates functional p53
in MPM [24,32]. Indeed, p53 negatively regulates the anti-
apoptotic protein survivin in ZL34 MPM cell line [24,32].
In the four cell lines that we used in the present study,
Activity of agonistic fully human anti-TRAIL death receptor monoclonal antibodies Mapatumumab and Lexatumumab in MPM  cell lines or primary cultures Figure 2
Activity of agonistic fully human anti-TRAIL death receptor monoclonal antibodies Mapatumumab and Lexa-
tumumab in MPM cell lines or primary cultures. MPM cell lines or primary cultures were treated with 0.01 µg/ml, 1 µg/
ml and 10 µg/ml Mapatumumab or Lexatumumab, and cell proliferation was determined by MTT assay 72 h thereafter. Absorb-
ance values obtained with untreated cells maintained under identical conditions were taken as 100%. Representative data of 
three independent experiments showing similar results are shown here.
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decreased survivin levels were observed only when a com-
bination of cisplatin with Mapatumumab or Lexatumu-
mab was used (Fig. 6A and 6B).
Taken together these results indicate that the synergism of
combined cisplatin and agonist TRAIL receptor treatment
is due to cross-talk between intrinsic and extrinsic apop-
totic pathways.
Cisplatin/TRAIL receptor antibodies-mediated cell death is 
inhibited by the antioxidant N-acetylcysteine
It has been shown that cisplatin sensitization to the tumor
necrosis factor receptor family member FasL is mediated
by generation of oxidative stress [33]. In order to investi-
gate whether the same mechanism was responsible for the
observed synergism of combined cisplatin and agonist
TRAIL receptor treatment we tested the effect of N-acetyl-
Cisplatin sensitizes MPM cells to Mapatumumab- or Lexatumumab- mediated cytotoxicity Figure 3
Cisplatin sensitizes MPM cells to Mapatumumab- or Lexatumumab- mediated cytotoxicity. Human agonistic 
TRAIL receptor antibodies Mapatumumab (Mapa) and Lexatumumab (Lexa) enhance the activity of cisplatin in MPM cells lines. 
H226 and ZL55 cells were cultured with or without 2 µM cisplatin for 24 h. Cells were subsequently left untreated or treated 
with 10 µg/ml Mapatumumab or Lexatumumab and cell proliferation was determined 72 h later as described under experimen-
tal procedures. Absorbance values obtained with untreated cells maintained under identical conditions were taken as 100%. 
Data represent means of three independent experiments and bars indicate standard deviations. **, P < 0.01 and *, P < 0.05 
compared to cells not treated with anti-TRAIL receptor antibodies.
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Table 2: Reduction in cell viability of MPM cells after incubation with Mapatumumab or Lexatumumab monoclonal antibodies. The 
percentage of reduction in cell viability was measured after incubation with 10 µg/ml Mapatumumab (Mapa) or Lexatumumab)Lexa) 
monoclonal antibodies. Data are expressed as mean ± s.d. from five independent experiments. **, P < 0.01 and *, P < 0.05 compared to 
untreated cells
Reduction in cell viability (%) induced by
MPM cell lines 10 µg/ml Mapa 10 µg/ml Lexa
Mapa and Lexa resistant (< 20% cell death)
H2052 3 ± 11 2 ± 9
SPC212 9 ± 5 * 7 ± 8
H226 5 ± 11 4 ± 6
more sensitive to Lexa
ZL5 9 ± 3 ** 77+11 **
H2452 7 ± 3 ** 52 ± 7 **
SDM4 9 ± 9 36 ± 9 **
SDM6 14 ± 14 37 ± 14 *
ZL34 8 ± 5 * 21 ± 10 **
SDM13 13 ± 3 * 22 ± 1 **
more sensitive to Mapa
H28 83 ± 2 ** 66 ± 20 *
MSTO-211H 48 ± 6 ** 24 ± 11 *
with similar sensitivity to Mapa and Lexa
SPC111 33 ± 14 ** 31 ± 11 **
ZL55 31 ± 6 ** 30 ± 9 **Molecular Cancer 2007, 6:66 http://www.molecular-cancer.com/content/6/1/66
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Synergy of concurrent treatment with anti-TRAIL receptor antibodies and cisplatin Figure 4
Synergy of concurrent treatment with anti-TRAIL receptor antibodies and cisplatin. Concurrent treatment with 
Lexatumumab (Lexa) monoclonal antibody enhances the activity of cisplatin in ZL5 MPM cells. ZL5 MPM cells were treated 
with single treatments or combinations of 2.12 µM cisplatin and/or 1.01 µg/ml Lexatumumab or fractions/multiples of those 
concentrations at a constant ratio from 0.25- to 4-fold. Responses were determined by MTT assay after 72 h and bars indicate 
standard deviations. Synergy was quantified by Combination Index (CI) analysis and expressed as CI versus fraction affected. By 
this method, CI<1 indicates synergy; CI = 1 indicates an additive effect; and CI>1 indicates antagonism. 96% confidence inter-
vals are shown on CI plots. Data shown represent mean values from three independent experiments. B and C. Concurrent 
treatment with Mapatumumab (Mapa) or Lexatumumab monoclonal antibodies enhance the cytotoxicity of cisplatin in H28 
cells. Experiments were performed as described under A, except that cisplatin, Mapatumumab and Lexatumumab were used at 
a concentration of 6.61 µM, 0.13 µg/ml and 0.40 µg/ml, respectively, and fractions/multiples thereof. Data represent means of 
three independent experiments and bars indicate standard deviations.
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cysteine (NAC), a well described scavenger of reactive oxy-
gen species (ROS). NAC significantly reduced cell death
by cisplatin and the combination treatment with cisplatin
and Mapatumumab in ZL55, H28 and ZL34 cell lines (Fig.
7), indicating that the generation of ROS contributes to
combination-induced cytotoxicity.
Discussion
With TRAIL and TRAIL-receptor agonistic antibodies
entering clinical trials for the treatment of patients with
cancer [11], the question has arisen whether molecular
markers can be identified, which would allow to select
patients benefiting from such therapy.
Our results indicate that the majority of MPM cell lines
(nine of thirteen) are sensitive to TRAIL. This is in contrast
to previous studies reporting on a small number of cell
lines only [19-22,34]. The potential advantage of targeting
TRAIL pathway via agonistic antibodies for its receptors
are the longer half-life compared to TRAIL and the higher
specificity [23]. In agreement with a previous report [20],
we have observed that MPM cells express membrane
TRAIL-R1 and TRAIL-R2, with higher TRAIL-R2 expres-
sion. Studies based on receptor-blocking antibodies indi-
cate that TRAIL can induce apoptosis through either
TRAIL-R1 or -R2 or both receptors, but the relative contri-
bution of each death receptor to apoptosis induction in
cells expressing both receptors is unknown [10]. TRAIL-R2
was shown to contribute more that TRAIL-R1 to TRAIL-
induced apoptosis in cells that express both death recep-
tors [35]. However, a recent study [28] has shown that
chronic lymphocytic leukaemia cells signal apoptosis
exclusively via TRAIL-R1 despite surface expression of
TRAIL-R2. Moreover, the apoptosis-inducing ability of
different TRAIL preparations in various cells demon-
strated an unanticipated preferential signalling via either
TRAIL-R1 or -R2 [28]. We found that the majority of MPM
cell lines were more sensitive to Lexatumumab (46%)
than to Mapatumumab, while a minority (15%) were
more sensitive to Mapatumumab than to Lexatumumab.
The activity of both antibodies was similar in 2 cell lines
(15%) and only few MPM cell lines were resistant to both
(23%). Taken together, these results suggest that there is a
permissive environment for preferential signalling via
TRAIL-R2 to death-receptor mediated apoptosis in MPM
cell lines expressing both receptors.
Comparison of TRAIL receptors expression levels and
TRAIL sensitivity of the MPM cell lines used in this study
did not reveal any consistent pattern, suggesting that
TRAIL sensitivity is not dependent on TRAIL-receptor
expression levels, thus indicating that other intracellular
mechanisms control TRAIL signal transduction in resist-
ant cells. TRAIL sensitivity can be regulated by anti-apop-
totic proteins such as Bcl-2, Bcl-XL or FLIP [20]. We have
shown in previous studies that Bcl-2 or Bcl-XL are abun-
dantly expressed in MPM and it has already been demon-
strated in MPM cells that downregulation of Bcl-XL is
associated to sensitization to TRAIL apotosis [36]. This
indicates that contrarily to what has been described in
melanoma cell lines [37], expression level of TRAIL death
receptors is not sufficient to identify MPM patients who
may respond to TRAIL or to TRAIL-receptor agonistic anti-
bodies.
No chemotherapy regimen for MPM has proven curative
[5,6,38,39]. Therefore, new therapeutic options for the
treatment of this malignancy need to be investigated.
There is accumulating evidence indicating a synergism
Effect of pre- and post-treatment with either Mapatumumab  or Lexatumumab on cisplatin cytotoxicity Figure 5
Effect of pre- and post-treatment with either Mapa-
tumumab or Lexatumumab on cisplatin cytotoxicity. 
A. Effects of pre- and post-treatment with Mapatumumab 
(Mapa) on cisplatin cytotoxicity in H28 cells. (X) H28 cells 
were pre-treated with 0.1 µg/ml Mapatumumab and incu-
bated for various times (0–24 h) followed by treatment with 
4.0 µM cisplatin and responses were determined by MTT 
assay after 48 h. (o) H28 cells were treated with 4.0 µM cis-
platin and post-treated with 0.1 µg/ml Mapatumumab after 
various times (0–24 h). Responses were determined by MTT 
assay after 48 h. B. Effect of pre- and post-treatment with 
Lexatumumab (Lexa) on cisplatin cytotoxicity in H28 cells. 
Experiments were performed as described in A, except that 
Lexatumumab at a concentration of 0.4 µg/ml was used 
instead of Mapatumumab. Absorbance values obtained with 
untreated cells maintained under identical conditions were 
taken as 100%. Data represent means of three independent 
experiments and bars indicate standard deviations.
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between anti-death receptor pathway and chemotherapy
in the induction of apoptosis, although the synergistic
mechanisms are not fully understood [40,41]. MPM cells
have been found by others to be resistant to TRAIL-
induced apoptosis, and require either chemotherapeutic
drugs or cycloheximide to be combined with TRAIL for
apoptosis to occur [19-21]. Our studies show that cispla-
tin synergistically enhances Mapatumumab- or Lexatu-
mumab-mediated apoptosis in a caspase-dependent
fashion and is also effective at promoting apoptosis when
used in combination with either Mapatumumab or Lexa-
tumumab in MPM tumor cells that are resistant to cispla-
tin, Mapatumumab or Lexatumumab single-agent
therapy. We observed a high heterogeneity in the response
of cell lines and primary cultures to treatment with TRAIL,
Mapatumumab, Lexatumumab or cisplatin or a combina-
tion thereof. Cytotoxic chemotherapeutic drugs sensitize
cultured cancer cells to TRAIL by different mechanisms
including up-regulation of the receptors [42], enhanced
death-inducing signalling complex formation or altera-
tion of the expression of pro-apoptotic/anti-apoptotic
proteins [31,43,44]. In previous studies, we showed that
the expression of the anti-apoptotic proteins Bcl-XL and
Bcl2 is highly variable in several MPM cell lines. This is
consistent with data observed in a recent study using a
large panel of MPM cell lines and tumors where highly
variable expression levels of five inhibitor of apoptosis
proteins, including survivin were found [45]. It is there-
fore likely that the observed differences in cell survival in
cell lines and primary cultures upon treatment with cispl-
atin and TRAIL receptor agonistic antibodies are due to
variation in basal expression levels of anti-apoptotic pro-
teins.
Combined treatment with TRAIL receptor antibodies and cisplatin increases cell death Figure 6
Combined treatment with TRAIL receptor antibodies and cisplatin increases cell death. H28, ZL5, ZL55 and 
H226 cells were cultured with or without 2 µM cisplatin for 24 h. Cells were then left untreated or treated with 10 µg/ml Map-
atumumab (Mapa) (A) or Lexatumumab (Lexa) (B) for 24 h. Lysates were analyzed by immunoblotting as described under 
material and methods.
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The synergistic cytotoxicity between cisplatin and Mapa-
tumumab or Lexatumumab is associated with an increase
of caspase-mediated apoptosis. Indeed, the combination
of cisplatin with Mapatumumab or Lexatumumab syner-
gistically enhanced caspase-8 and Bid activation in MPM
cells sensitive to antibody treatment and caspase-3 activa-
tion in all cells treated with a combination of cisplatin
and Mapatumumab or Lexatumumab. In a previous study
we have demonstrated that p53 is functional in MPM cells
and that it negatively regulates the anti-apoptotic protein
survivin [24,32]. Combination of cisplatin with Mapatu-
mumab or Lexatumumab further increased the expression
of p53 transcriptional targets Bax and decreased survivin,
compared to the treatment with either agent alone. Simi-
larly, decrease in anti-apoptotic Mcl-1 expression was
observed upon exposing MPM cells to the combination of
cisplatin with Mapatumumab or Lexatumumab, confirm-
ing the significant role of these proteins in the enhance-
ment of death receptor-mediated apoptosis by cisplatin in
MPM cells. Based on the scavenging effect of the antioxi-
dant antioxidant NAC on cell death induced either by cis-
platin and the combination of Mapatumumab and
cisplatin, we infer that the molecular mechanism respon-
sible for the synergism is linked to the production of reac-
tive oxygen species, which act as positive regulator of
apoptosis. The role of cisplatin-induced oxidative stress in
the enhancement of the efficiency of TNF family members
has already been described in MPM cell lines after treat-
ment with cisplatin, FasL or the combination thereof [33].
Our findings are also in agreement with a study showing
The antioxidant NAC reduces cell death induced by either cisplatin, Mapatumumab or a combination thereof Figure 7
The antioxidant NAC reduces cell death induced by either cisplatin, Mapatumumab or a combination thereof. 
The MPM cell lines H28, ZL55 and ZL34 were treated with cisplatin (6.61 µM, 6.0 µM, and 6.0 uM, respectively) and 24 h later 
with Mapatumumab (0.13 µg/ml, 10 µg/ml, 10 µg/ml, respectively) as indicated, either in the presence or absence of NAC (5 
mM). Cell proliferation was determined by MTT assay 48 h thereafter. Absorbance values obtained with untreated cells main-
tained under identical conditions were taken as 100%. Data represent means of at least three independent experiments and 
bars indicate standard deviations. **, P < 0.01 and *, P < 0.05 compared to cells treated in the absence of NAC but otherwise 
maintained under identical conditions.
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that the generation of ROS sensitizes colon cancer cells to
death-inducing ligand TRAIL [46] and with a study show-
ing that ROS generation by Sulforaphane is pivotal for the
sensitization of hepatoma cells to TRAIL-induced apopto-
sis [47].
Contrary to what has been observed in squamous cell car-
cinoma and the ligand TRAIL [31], we have observed that
pre-treatment with cisplatin followed by treatment with
Mapatumumab or Lexatumumab resulted in significantly
higher cytotoxic effects in MPM cell lines than when the
sequence was reversed. The reasons for such a difference
are not clear and can include different kinetics of apop-
totic pathways in different cell lines [48] and/or dosage.
Conclusion
In summary, our results indicate that the sequential
administration of cisplatin followed by the human ago-
nistic TRAIL receptor antibodies Mapatumumab or Lexa-
tumumab deserve investigation in the treatment of
patients with MPM.
Methods
Cell culture and reagents
The MPM cell lines SCP212, ZL34,, SPC111, ZL5, ZL55
and the primary cultures SDM4 SDM6 and SDM13 were
generated in our laboratory and have been described pre-
viously [24,25]. The MPM cell lines H2052, H226,
H2452, H28 and MST0-211H were obtained from ATCC
(LGC Promochem Sarl, France). All cells were maintained
in RPMI 1640 (Sigma, St. Louis, MO, USA) supplemented
with 2 mM L-glutamine, 1 mM sodium pyruvate, 10% FBS
and 1% (w/v) penicillin/streptomycin. Jurkat cells were
obtained from ATCC and maintained in RPMI 1640
medium (Sigma) supplemented with 5% FBS (Invitrogen,
Paisley, UK), 15 mM HEPES, 2 mM L-glutamine, 50 µM β-
mercaptoethanol and 1% (w/v) penicillin/streptomycin
(Invitrogen). All cells were grown at 37°C in a humidified
atmosphere containing 5% CO2.
Reagents
Recombinant human polyhistidine-tagged TRAIL (His-
TRAIL) and antibodies to TRAIL-R1, TRAIL-R2, TRAIL-R3
and TRAIL-R4 were purchased from Alexis (Lausen, Swit-
zerland). The agonistic monoclonal antibodies against
TRAIL-R1 (Mapatumumab) and TRAIL-R2 (Lexatumu-
mab) were provided by Human Genome Sciences (Rock-
ville, MD, USA). The following antibodies were
purchased: caspase-8 (Alexis, Lausen, Switzerland), Bid
(R&D Systems, Minneapolis, MN, USA), Mcl-1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), ICAD (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), caspase-3 (BD
PharMingen, San Diego, CA, USA), Bax (Santa Cruz Bio-
technology, Santa Cruz, CA, USA), survivin (R&D Sys-
tems, Minneapolis, MN, USA), and actin (ICN
Biomedicals, Irvine, CA, USA). Where indicated, either
cisplatin (Bristol-Myers Squibb AG, Baar, Switzerland)
and/or N-acetyl-L-cysteine (ALEXIS Corporation, Lausen,
Switzerland) were added.
Measurement of cell growth
Cell growth was determined using colorimetric cell viabil-
ity assay based on the reduction of tetrazolium salt MTT,
as described [49]. Cells were plated in quadruplicate in
96-well plates (7500 cells/well) and absorbance was
measured using a SPECTRAmax 340 microplate reader.
Cell growth was calculated as a percentage of the absorb-
ance signal obtained with wells of untreated (viable) cells
kept under identical conditions. Dose curve plots, IC50
and Combination Index (CI) were calculated by using
CalcuSyn software from BIOSOFT.
Immunoblotting
Cells were lysed for 30 min with 1× RIPA buffer (Upstate)
containing 0.1% SDS, 1 mM PMSF and complete protease
inhibitor cocktail (ROCHE). Lysates were clarified by cen-
trifugation (10,000g for 30 min at 4°C) and protein con-
centrations were determined using BCA (Pierce/Perbio
Science S.A., Lausanne, Switzerland). After SDS/PAGE
separation, the protein was transferred to nitrocellulose
membrane and immunoblotting was performed as
described [50] using the specific antibodies mentioned
above.
Flow cytometric analysis
Immunostaining of intact cells was performed as
described previously. Surface expression of TRAIL recep-
tors was evaluated by indirect immunostaining using the
primary antibodies mentioned above followed by PE-con-
jugated anti-mouse secondary antibodies (Alexis Bio-
chemicals). Nonspecific fluorescence was assessed using
normal mouse immunoglobulin G (IgG) followed by sec-
ondary antibodies. Flow cytometric analyses were per-
formed using a FACSCalibur (FACScan, BD Biosciences,
San Jose, CA, USA).
Statistical analysis
Data are presented as the mean ± SE of at least three inde-
pendent experiments. Statistical differences were assessed
using two-sided unpaired Student's t test and P values <
0.05 were considered significant.
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